Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Pediatr Hematol Oncol ; 45(1): e139-e141, 2023 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-35665709

RESUMEN

Patients with DNA double-strand breakage repair disorders are at increased risk of malignancy which is often difficult to treat given underlying sensitivity to chemotherapy and radiotherapy, lending an important role to hematopoietic stem cell transplantation. The choice of conditioning regimen used must balance reducing risk of rejection with minimizing excessive toxicity from myeloablative chemotherapy or ionizing radiation. We describe successful engraftment following a nonmyeloablative hematopoietic stem cell transplantation in a patient with Ligase IV syndrome and numerous pretransplant complications including malignancy, cardiac failure, and secondary hemophagocytic lymphohistiocytosis. Congruent with prior reports, a reduced intensity regimen appears efficacious in Ligase IV syndrome patients.


Asunto(s)
Enfermedad Injerto contra Huésped , Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda , Humanos , Médula Ósea , Enfermedad Injerto contra Huésped/etiología , Donante no Emparentado , Trasplante Homólogo/efectos adversos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Leucemia Mieloide Aguda/complicaciones , Acondicionamiento Pretrasplante/efectos adversos
2.
J Pediatr Hematol Oncol ; 43(2): e276-e279, 2021 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-32079988

RESUMEN

Cystic angiomatosis (CA) is a rare disease characterized by the proliferation of vascular and lymphatic channels lined by a single layer of endothelial cells. CA may present with isolated skeletal or visceral disease. There is no consensus for the standard of care in these patients, and diverse regimens for CA have been reported, including observation, surgery, radiation, and a variety of medical therapies. We present a case of multifocal, isolated skeletal CA, treated with close observation alone and review the literature. We suggest that these cases may be safely followed without intervention and may be stable for prolonged periods of time.


Asunto(s)
Angiomatosis/diagnóstico , Enfermedades Asintomáticas , Enfermedades Óseas/diagnóstico , Quistes/diagnóstico , Niño , Femenino , Humanos , Pronóstico
4.
PLoS One ; 15(4): e0232036, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32343715

RESUMEN

The NUP98 and NUP214 nucleoporins (NUPs) are recurrently fused to heterologous proteins in leukemia. The resulting chimeric oncoproteins retain the phenylalanine-glycine (FG) repeat motifs of the NUP moiety that mediate interaction with the nuclear export receptor Crm1. NUP fusion leukemias are characterized by HOXA gene upregulation; however, their molecular pathogenesis remains poorly understood. To investigate the role of Crm1 in mediating the leukemogenic properties of NUP chimeric proteins, we took advantage of the Sequestosome-1 (SQSTM1)-NUP214 fusion. SQSTM1-NUP214 retains only a short C-terminal portion of NUP214 which contains FG motifs that mediate interaction with Crm1. We introduced point mutations targeting these FG motifs and found that the ability of the resulting SQSTM1-NUP214FGmut protein to interact with Crm1 was reduced by more than 50% compared with SQSTM1-NUP214. Mutation of FG motifs affected transforming potential: while SQSTM1-NUP214 impaired myeloid maturation and conferred robust colony formation to transduced hematopoietic progenitors in a serial replating assay, the effect of SQSTM1-NUP214FGmut was considerably diminished. Moreover, SQSTM1-NUP214 caused myeloid leukemia in all transplanted mice, whereas none of the SQSTM1-NUP214FGmut reconstituted mice developed leukemia. These oncogenic effects coincided with the ability of SQSTM1-NUP214 and SQSTM1-NUP214FGmut to upregulate the expression of Hoxa and Meis1 genes in hematopoietic progenitors. Indeed, chromatin immunoprecipitation assays demonstrated that impaired SQSTM1-NUP214 interaction with Crm1 correlated with impaired binding of the fusion protein to Hoxa and Meis1 genes. These findings highlight the importance of Crm1 in mediating the leukemogenic properties of SQSTM1-NUP214, and suggest a conserved role of Crm1 in recruiting oncoproteins to their effector genes.


Asunto(s)
Proteínas de Homeodominio/genética , Carioferinas/metabolismo , Leucemia/metabolismo , Proteína 1 del Sitio de Integración Viral Ecotrópica Mieloide/genética , Proteínas de Complejo Poro Nuclear/genética , Proteínas de Fusión Oncogénica/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Proteína Sequestosoma-1/genética , Secuencias de Aminoácidos , Animales , Línea Celular , Regulación Neoplásica de la Expresión Génica , Leucemia/genética , Leucemia/patología , Ratones , Mutagénesis Sitio-Dirigida , Trasplante de Neoplasias , Proteínas de Complejo Poro Nuclear/química , Proteínas de Fusión Oncogénica/química , Proteínas de Fusión Oncogénica/genética , Mutación Puntual , Regulación hacia Arriba , Proteína Exportina 1
5.
J Pediatr Hematol Oncol ; 40(7): e442-e445, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29334537

RESUMEN

Central nervous system (CNS) chloromas are an exceedingly rare presentation of CNS relapse in acute lymphoblastic leukemia (ALL). We report a relapsed ALL patient who presented with 2 separate chloromas and cerebrospinal fluid lymphoblastocytosis, and outline a treatment plan of systemic chemotherapy and CNS-directed radiation therapy. A review of the literature indicates that multiagent chemotherapy combined with CNS radiotherapy is effective, with hematopoietic stem cell transplantation used in half of reported cases. We conclude that intensive systemic multiagent chemotherapy with CNS-directed radiation therapy can be successfully used to treat relapsed pediatric ALL with CNS lymphoblastic chloroma.


Asunto(s)
Neoplasias del Sistema Nervioso Central/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Sarcoma Mieloide/terapia , Neoplasias del Sistema Nervioso Central/tratamiento farmacológico , Neoplasias del Sistema Nervioso Central/radioterapia , Líquido Cefalorraquídeo , Quimioterapia Adyuvante , Niño , Terapia Combinada/métodos , Trasplante de Células Madre Hematopoyéticas , Humanos , Radioterapia Adyuvante , Recurrencia , Sarcoma Mieloide/tratamiento farmacológico , Sarcoma Mieloide/radioterapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...